EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, announces that a general meeting of the Company will be held at the offices of Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD at 11:00 a.m. on 27 July 2017 (the 'General Meeting') for the purpose of considering and, if thought fit, approving resolutions to cancel the share premium reserve of the Company and to grant the Company the general authority to make market purchases of its own shares.
The cancellation is necessary in order for the Company to proceed with its previously announced share buyback plan of up to 15% of the Company's current issued share capital.
A copy of a circular containing the notice convening the General Meeting and form of proxy will be posted to shareholders later today and will shortly be available on the Company's website, www.ekfdiagnostics.com in accordance with AIM Rule 20.
EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO | www.ekfdiagnostics.com Tel: 00 44 29 2071 0570 |
N+1 Singer (Nomad & Broker) Alex Price / Shaun Dobson / Ali Laughton-Scott | Tel: 020 7496 3000 |
Walbrook PR Limited |
Tel: 020 7933 8780 or ekf@walbrookpr.com Mob: 07980 541 893 / 07584 391 303 |
EKF Diagnostics Holdings plc published this content on 26 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 June 2017 06:54:09 UTC.
Original documenthttps://www.ekfdiagnostics.com/notice-of-general-meeting.html
Public permalinkhttp://www.publicnow.com/view/686FAFD7BDCEBDABB69F4B5C276D9C57A7258E99